Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

@article{Stessman2013ProfilingBR,
  title={Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.},
  author={Holly A. F. Stessman and Linda B Baughn and Aaron Sarver and Tian Xia and Raamesh Deshpande and Aatif Mansoor and Susan A. Walsh and John J. Sunderland and Nathan G. Dolloff and Michael Andrew Linden and Fenghuang Zhan and Siegfried Janz and Chad L. Myers and Brian G. Van Ness},
  journal={Molecular cancer therapeutics},
  year={2013},
  volume={12 6},
  pages={1140-50}
}
Multiple myeloma is a hematologic malignancy characterized by the proliferation of neoplastic plasma cells in the bone marrow. Although the first-to-market proteasome inhibitor bortezomib (Velcade) has been successfully used to treat patients with myeloma, drug resistance remains an emerging problem. In this study, we identify signatures of bortezomib sensitivity and resistance by gene expression profiling (GEP) using pairs of bortezomib-sensitive (BzS) and bortezomib-resistant (BzR) cell lines… CONTINUE READING